**Core tip:** Hepatocellular carcinoma (HCC) is a tumor usually arising from previous hepatic diseases as cirrhosis and chronic hepatitis B and C infections. Several studies have shown that a key factor for HCC oncogenesis is chronic inflammation. Inflammation induces changes in the gene expression pattern in surrounding cells. These changes provide an environment with a high level of cytokines, promoting hepatocyte transformation to tumor cells. New therapies against HCC are focused on regulating stromal cells within the tumor microenvironment to avoid HCC progression.

INTRODUCTION
============

Liver is a vital organ responsible for hundreds of chemical reactions. Among them, it is involved in metabolizing many toxins. These reactions are carried out by the hepatocytes, which represent around 80% of the hepatic tissue cell population. Since the liver is the main detoxifying organ, hepatocytes are exposed to many toxins\[[@B1]\] which may cause insults inducing several anomalies, such as primary liver cancer. There are two types of adult primary liver cancers: cholangiocarcinoma and hepatocellular carcinoma (HCC), the latter being responsible for 85% to 90%\[[@B2]\] of total primary liver cancer instances. HCC is one of the deadliest malignancies worldwide\[[@B3]\]. It can be preceded by chronic inflammation due to cirrhosis, hepatitis B virus or hepatitis C virus infections, all of which increase 20-fold the risk of liver cancer\[[@B4]\].

Hepatocytes have a high regeneration rate, being controlled by multiple growth factors. The first molecule discovered with the ability to stimulate hepatocyte division was hepatocyte growth factor (HGF). HGF is expressed and released by specialized non-parenchymal cells called hepatocyte stellate cells. These cells release HGF into the extracellular space, where it acts in a paracrine manner on its receptor, known as c-Met, which is located on the surface of hepatocytes. HGF was characterized as a potent mitogen due to its ability to induce c-Met dimerization. This activates a canonical signal transduction pathway including effector molecules such as RAS-ERK and PI3K-AKT, which increase DNA synthesis and increase cell cycle progression.

The first therapies developed to treat HCC were focused on inhibiting the HGF/c-Met axis, thus stopping hepatocytes in the G1 phase of the cell cycle\[[@B5]\]. Studies in mice have shown that HGF or c-Met deletion are lethal\[[@B6]\]. Moreover, some tumors overexpress these proteins. Therapies targeting HGF or c-Met have been used for years. However, patients receiving these therapies still presented high rates of mortality, as well resistance to chemotherapy, radiotherapy, immunotherapy or hormonal therapy\[[@B7]\].

Recently, novel studies have elucidated other noncanonical signaling pathways that are modified in HCC. It is also now known that the fate of hepatocytes is determined by the interaction with nearby stromal cells. New therapies are being developed targeting the tumor microenvironment, including endothelial cells, immune cells, fibroblasts and the extracellular matrix.

Nonetheless, HGF/c-Met levels are currently being used to predict tumor aggressiveness and the prognosis of HCC patients.

In this review, we have analyzed HCC literature to generate a comprehensive view about the molecular processes already known and important discoveries that remain to be made.

HGF AND c-MET
=============

The *HGF* gene is located on chromosome 7q21. It contains 20 exons and is expressed by mesenchymal cells. Hepatocyte growth factor (HGF) is a member of the peptidase S1 family of serine proteases, although it lacks peptidase activity. This protein is synthesized as an inactive pro-peptide generating an alpha/beta heterodimer linked by a disulfide bond. Proteolytic conversion of pro-HGF to HGF can be mediated by three enzymes present in the tumor environment: matriptase, hepsin and HGF activator (HGFA). However, there is evidence that urokinase plasminogen activator (uPA), transmembrane protease, serine 13 (TMPRSS13)\[[@B8]\] may also activate it. Although HGF was originally identified as a hepatocyte mitogen, it is now known to be a cytokine with pleiotropic effects. It has roles in enhancing angiogenesis, immune response, cell motility, and cell differentiation.

The gene for c-Met is located in chromosome 7q21-31 and contains 24 exons. Its promoter region, however, is located in chromosome 1. c-Met is expressed in epithelial cells. c-Met is a single pass tyrosine kinase receptor made up of an alpha and a beta subunit linked by disulfide bonds. The beta subunit is a transmembrane monomer that contains 5 catalytic tyrosines in its cytoplasmic tail. Y1003 negatively regulates c-Met by linking it to the ubiquitin ligase casitas beta-lineage lymphoma (c-CBL)\[[@B9]\]. In contrast, Y1234; Y1235; Y1349 and Y1356 positively regulate c-Met. Furthermore, S985 in c-Met can be phosphorylated by protein kinase-C, inducing c-Met degradation (ubiquitination and endocytosis) \[[@B10]\].

c-Met activation has pleiotropic effects because its cytoplasmic domain can interact with multiple proteins involved in several cellular signaling pathways. Because of this, c-Met is considered an oncogene involved in cell proliferation, invasion, motility, angiogenesis and apoptosis.

SIGNALING PATHWAYS IN HCC
=========================

The pathophysiology of hepatocellular carcinoma at a cellular level is complex and it is very possible that there are many unknown c-Met interactions with others signaling pathways. Multiple cell pathways are aberrant in HCC, but this review just focuses on the signaling pathways related to c-Met. The activation of c-Met can take place by the canonical pathway, which involves HGF binding to c-Met resulting in c-Met homodimerization. It can also take place through non-canonical pathways, where c-Met dimerizes with different receptors.

Heterodimers of receptor proteins and c-Met are involved in overstimulation and dysregulation of c-Met signaling pathways. This occurs during hypoxia, which can cause c-Met overexpression, mutations on tyrosine kinase domain or *HGF* gene amplification\[[@B11]\]. However, this latter event rarely occurs in HCC\[[@B12]\].

c-Met canonical downstream signaling pathways
---------------------------------------------

These signaling pathways involve proteins with SH2 domains or phosphotyrosine-binding domains that are able to interact with phosphorylated tyrosine residues\[[@B13]\] that, in turn, interact physically with the cytoplasmic domain of c-Met.

**Growth factor receptor-bound protein 2 (Grb-2):** Grb-2 interacts with Y1356 of c-Met to transduce HGF signaling to the cytoplasm. Grb-2 is considered a key protein in HGF/c-Met axis because it connects to several signaling transducers, such as Ras, SOS, and Gab1. Grb-2 is involved in cell motility, cycle progression, angiogenesis, amongst other.

**GRB2-associated binding protein 1 (Gab1):** Activated c-Met is phosphorylated on Y1349 and Y1356 residues which specifically interact and phosphorylate to Gab1. However, Gab1 can also be phosphorylated by Grb-2. Gab1 is involved in many signal transduction pathways by binding to effector proteins that have a role in cell motility and extracellular matrix invasion, such as Shp2, Shc, PLCγ1, p120\[[@B14]\].

**Phosphoinositide 3 kinase (PI3K):** PI3K is an enzyme able to phosphorylate proteins downstream of c-Met thereby linking oncogenes and many receptors essential for cellular functions. The phospho Y1356 in c-Met can phosphorylate PI3K, inducing cell mobility\[[@B9]\] by activating focal adhesion kinase (FAK). However, PI3K can also be activated by Gab1 where it promotes cell survival\[[@B11]\].

**Signal transducer and activator of transcription 3 (STAT3):** HGF binds to c-Met inducing the phosphorylation on Y1356. This phosphorylated amino acid interacts and actives STAT3, as was shown by Boccaccio et al\[[@B15]\]. When it is activated, it translocates to the nucleus where it binds to DNA and promotes gene expression (related with angiogenesis, and long-term response)\[[@B15]\].

**Shc-transforming protein 1 (Shc):** SHC is an adaptor protein involved in the mitogenic signal transduction from tyrosine receptors. On the other hand, experiments carried out in fibroblast showed that Shc is highly stimulated by VEGF and that activation correlated with the angiogenic response\[[@B16]\].

Non-canonical c-Met signaling pathways
--------------------------------------

c-Met activation by non-canonical pathways takes place when this receptor is over-expressed and dimerizes with other receptor subunits, or may bind to ligands other than HGF. Non-canonical pathways are usually associated with c-Met gene amplification, and are common in treatment resistant cancers\[[@B17],[@B18]\], tumor progression, and metastasis, as shown in *in vivo* experiments using mice\[[@B19],[@B20]\]. It has also been reported that c-Met dimerization takes place in the absence of ligand binding\[[@B21]\] when it interacts with the following proteins:

**Epithelial growth factor receptor (EGFR):** Physical interaction between EGFR and c-Met was found in A431 cells\[[@B22]\]. In HCC, the transactivation between these two receptors takes place, inducing the common downstream signaling effectors PI3K and Ras\[[@B23]\].

**Human epidermal growth factor receptor (HER):** The dimerization between c-Met and HER increases activation of PI3K/AKT signaling\[[@B18]\], which is associated with resistance to EGFR inhibitors\[[@B24]\] as well as cancer progression.

**Integrin** α**~6~**β**~4~:** Trusolino et al\[[@B25]\] determined that integrin α~6~β~4~ physically interacts with c-Met on the membrane surface of carcinoma cells. This protein is necessary for cancer invasion because the cytosolic domain of β4 induces c-Met activation. In this case, the signaling transduction is performed by Shc and PI3K\[[@B14]\].

β**-catenin (**β**-CAT):** Phosphorylated β-CAT may bind to c-Met, activating its downstream signaling. Phosphorylation of Y654 in β-CAT actives FAK, which induces cyclin D1 (CKD1) expression\[[@B26]\]. At the same time, β-catenin is translocated to the nucleus, and promotes c-myc gene expression\[[@B27]\].

**Receptor for hyaluronic acid (CD44):** The CD44v3 splice variant is the CD44 isoform with high affinity for heparin domains. This v3 may be activated by different growth factors with heparin domains, such as fibroblast growth factor (FGF) and HGF. CD44 may act as a concentrator of HGF to present it to c-Met resulting in downstream signaling transduction\[[@B28]\]. On the other hand, Olaku et al\[[@B29]\] reported that CD44v6 splice variant is necessary for c-Met activation. It is thought that three specific amino acid residues (RWH in human) in v6 are necessary for complete c-Met activation.

**ICAM-1:** This protein can substitute for the role of CD44v6 in c-Met activation, as shown in hepatocytes from Cd44 null mice\[[@B29]\].

**Plexin B1:** Receptor with high similarity to c-Met, which is also expressed in the same tissues as c-Met. After mutation and expression of exogenous c-Met in cells, Giordano et al\[[@B30]\] shown that plexin B1 links to c-Met when it is activated by semaphorin 4D. This interaction was reported in invasive cancer cells growing in response to semaphorin 4D.

**Vascular endothelial growth factor A (VEGF-A):** HGF can induce VEGF expression\[[@B31]\] by phosphorylation of a key transcription factor called Sp1. This characteristic of HGF increases the expression of Bcl-2\[[@B32]\], which acts as an antiapoptotic protein.

**Insulin receptor (INSR) tyrosine kinase:** This receptor has an extracellular α-chain and a transmembrane β-chain. This protein has a very similar structure compared to c-Met. Furthermore, it has been reported that insulin and HGF can phosphorylate INSR in its Y1146 and Y1150 or Y1151 residues. In HCC cells, Y1322 is also phosphorylated, thus activating PI3K. HGF-stimulated hepatocytes have shown to form a INSR-c-Met complex. There is evidence that c-Met can also phosphorylate insulin receptor substrates (IRS) on Y895. Likewise, INSR phosphorylates IRS on Y612\[[@B33]\]. In summary, both c-Met and IRS increase downstream signaling through PI3K-AKT, promoting cell growth, cell survival and cell motility.

**Fas:** This protein is one of the surface death receptors and triggers apoptosis signaling when binds its ligand (FasL). Wang et al\[[@B34]\] showed that Fas and c-Met associate with each other using coimmunoprecipitation experiments in Hep G2 cells. These authors proposed that c-Met promotes cell survival by two different pathways. (1) When there are low levels of FasL in the microenvironment, Fas binds to c-Met avoiding to trigger its intracellular signaling pathway. (2) However, in the presence of high levels of HGF, c-Met releases Fas activating death receptor-mediated apoptosis. Nevertheless, the c-Met/Fas signaling pathway ratio is so high that cells activate antiapoptotic signals through PI3K/AKT/Bad axis to prevent Fas-mediated apoptosis.

**Mucin 1 (MUC1):** MUC1 expression is increased during transformation from the normal liver to HCC, as was described by Bozkaya et al\[[@B35]\] MUC1 silencing in HCC cells leads to β-catenin activation and c-Myc expression. Under this condition, high levels of HGF in the microenvironment increase cellular motility and invasiveness\[[@B35]\]. However, there are also contradicting studies. For instance, Singh et al\[[@B36]\] reported that MUC1-induced c-Met activation by physical interaction decreased MMP-1 transcription and cell motility\[[@B36]\].

**Neuropilin-1 and -2 (Nrp-1, -2):** Neuropilins are a family of transmembrane glycoproteins involved in several processes, including axonal guidance, angiogenesis, tumorigenesis, and immunologic response. Nrp-1 can bind VEGF-A~165~, VEGF-B, VEGF-E, and placental growth factor (PIGF). On the other hand, Nrp-2 can bind class III semaphorins and VEGF proteins (VEGF-A~165~, VEGF-A~145~, and VEGF-C). Nrp-2 binds VEGF proteins, and increases the VEGFR-2 phosphorylation threshold, promoting migration, and sprouting cells\[[@B37]\]. Nrp-2 and VEGFR2 can bind each other enhancing the signaling initiated by the HGF/c-Met axis. Moreover, Nrp-1 and Nrp-2 interact with other receptor tyrosine kinase, such as VEGFRs\[[@B37]\]. Neuropilins have a short cytoplasmic domain to act as catalytic domain. This evidence suggests that the intracellular domain may present a binding site involved in kinase signal transduction\[[@B37]\].

**Focal adhesion kinase (FAK):** Studies carried out in MEFs and HEK293 cells showed that FAK interacts directly with c-Met\[[@B38]\]. FAK is a non-receptor tyrosine kinase involved in several cell signaling pathways. Notably, it is well characterized for its role in formation and disassembly of focal adhesions, as well as cell protrusions\[[@B26]\]. However, FAK is also intimately involved in the regulation of cell proliferation because it is able to phosphorylate PI3K and ERK. Experiments in FAK knockout mice revealed suppressed hepatocarcinogenesis due to decreased PI3K and ERK signaling pathways\[[@B26]\].

Collectively, these pathways are responsible for promoting initiation and progression of HCC (Figure [1](#F1){ref-type="fig"}).

![Representation of hepatocyte growth factor/c-Met canonical and non-canonical pathways in hepatocytes. Canonical pathway is activated by HGF release from stromal cells, and subsequent binding to the c-Met receptor inducing c-Met dimerization. Activated c-Met binds Gab-1, Grb-2, Shc, and STAT3. These proteins are involved in signal transduction regulating cell proliferation, migration, differentiation, or invasion, depending on the activated downstream proteins. The scheme represents the proteins described in the canonical pathway, but not all of the proteins involved in executing their cell activity. Non-canonical pathways are activated when a c-Met monomer binds to a monomer of another kind of receptor, or when a c-Met homodimer binds FAK or β-catenin on its cytoplasmic domain. The arrows represent different proteins performing different cell activities. HGF: Hepatocyte growth factor.](WJG-24-3695-g001){#F1}

The expression of HGF is decreased in HCC, but it is increased in the surrounding tissue. On the other hand, c-Met is expressed in HCC at higher levels than in the surrounding tissue. These observations suggest that the overexpression of c-Met, together with additional oncogenes, is responsible of HCC aggressiveness\[[@B39]\].

MICROENVIRONMENT IN HCC
=======================

Microenvironment is created by extracellular matrix (ECM) and stromal cells. Stromal cells, such as endothelial cells, fibroblasts, and immune cells, increase the gene expression and release of chemokines, cytokines, proteases and growth factors, such as HGF\[[@B40]\]. HGF released from stromal cells interacts with hepatocytes enhancing HGF/c-Met signaling transduction. Subsequently, hepatocytes intensify cell survival and cell proliferation. HGF may also modify cell-cell interaction, and cell-extracellular matrix interactions through activating proteolytic networks\[[@B41],[@B42]\]. Furthermore, stromal cells increase the gene expression of HGF. Furthermore, HGF promotes angiogenesis from endothelial cells around the chronic liver disease.

Angiogenesis and lymphangiogenesis
----------------------------------

The initial stages of liver tumor are characterized by hypoxia, a condition leading to the release of VEGF to increase tumor vascularization. In parallel, immune cells contribute to the activation of the vascularization process by releasing inflammatory mediators, including interleukin-1α (IL-1α), IL-1β, tumor necrosis factor-α, and prostaglandin E2. HCC is a highly vascularized tumor. However, the new blood vessels formed to irrigate the tumor mass present abnormalities, such as tortuous vessels and sinusoidal capillarization. Tumor blood vessels have incomplete basal membrane and incomplete pericyte coverage. Simultaneously, lymphangiogenesis, proliferation and sprouting of new lymphatic vessels from preexisting ones, also takes places. Lymphangiogenesis is tightly regulated by lymphoangiogenic growth factors, such as VEGF-C and VEGF-D, released from tumor and stromal cells. VEGF-C and VEGF-D interact with VEGFR-2 and VEGFR-3, respectively, in lymphatic cells. VEGFR-2 is responsible for vessel enlargement, whereas VEGFR-3 is critical for lymphangiogenic sprouting\[[@B43]\]. However, VEGF-A may interact with VEGFR-3. Further, venous and lymphatic endothelial cells express neuropilin-2 (Nrp-2), a protein that it has recently been associated to lymphatic cell survival and migration\[[@B37]\]. On the other hand, Nrp-2 is not involved in venous or lymphatic cell proliferation\[[@B44]\]. Tumor-associated lymphatic vessels express stromal cell-derived factor 1 (CXCL12), and tumor cells express the receptor for CXCL12, called C-X-C chemokine receptor 4 (CXCR4). Tumor cells have upregulated CXCR4 under hypoxia conditions. However, hypoxia promotes migration of metastatic cells into the tumor-draining lymph node. Endothelial and lymphatic cell survival and cell proliferation promote tumor metastasis. In fact, high densities of vascular and lymphatic vessels are correlated with high patient lethality\[[@B44]\].

Inflammation
------------

The role of immune cells in cancer is controversial, because they can eliminate tumor cells in their initial stages, but, due to their generation of oxidative stress and DNA damage, they may also promote cancer development.

A study carried out in a small cohort showed that patients with viral hepatitis presented high neutrophil levels and low lymphocyte levels. This has been proposed as a substitute parameter to determine initial development HCC stages, because neutrophils are the first kind of immune cells to interact with tumor cells\[[@B45]\]. Neutrophils located in the tumor mass are responsible for promoting inflammation and facilitating tumor progression. From the same study, the authors detected high platelet levels in circulation. This association might be caused because platelets are responsible for activating neutrophils, enabling neutrophils to migrate through blood vessels. A lower risk of HCC was shown with anti-platelet therapy from another independent study\[[@B46]\]. Additionally, platelets are key effectors to enhance the accumulation of CD8^+^ T lymphocytes and mediate immune injury, intensifying the micro-inflammation.

Tumor-infiltrating T cells are regulated by VEGF-A and VEGF-C, as well as their release into the tumor microenvironment, cell proliferation phenotype, and activity\[[@B47]\].

Macrophages are responsible for digesting all damaged cells in the tissues including cancer cells. However, macrophages activated by inflammatory cytokines from the tumor microenvironment, express the PD-L1 protein. This results in them adopting a suppressive macrophage phenotype, avoiding tumor-specific T cell immunity and increasing HCC progression\[[@B48]\]. These macrophages activated by the tumor microenvironment express tumor necrosis factor α (TNF-α), which induces c-Met-expression on their surface. These macrophages also express MMP-9, which increases the remodeling of the tumor microenvironment of HCC\[[@B49]\].

Fibroblasts and hepatic progenitor stem cells
---------------------------------------------

Fibroblasts are an important cell population in the microenvironment, and have a prominent role in tumor cell progression and metastasis. Fibroblasts have key functions in the tumor microenvironment: (1) synthesis and remodeling of the ECM; and (2) release of multiple cytokines and chemokines to promote inflammation, angiogenesis and epithelial differentiation. Tumor-associated fibroblasts acquire a modified phenotype induced by transforming growth factor-β (TGFβ), and become hepatic progenitor cancer cells (HPCs)\[[@B50]\].

HPCs have the ability to differentiate to several kinds of cells depending on the stimulus from their microenvironment. Under the influence of a tumor microenvironment, HPCs acquire genetic and epigenetic mutations, inducing their transformation from HPCs to cancer stem cells (CSCs)\[[@B51]\]. CSCs are able to perpetuate themselves through self-renewal, and generate mature cells of a particular tissue through differentiation, supporting tumor cell proliferation\[[@B52]\]. Likewise, CSCs have been proposed to be the clonogenic core of HCC, sustain the primary tumor, confer drug resistance, promote metastasis, and promote angiogenesis.

Fibrosis
--------

All of the stages described above in the present section, cell transvasation, cell-cell interaction, oxidative stress, cytokines and proteases released into the tumor microenvironment, provoke changes and deregulation in the ECM. The deregulation of ECM is characterized by increasing deposition of fibronectin, fibrillar collagen types I and II into the liver. This ECM deregulation decreases liver plasticity, increasing ECM stiffness, cell survival and cell proliferation of tumor cells. These processes are mediated by integrin signaling pathways, such as α~1~β~1~ and α~2~β~1~. Moreover, the ECM increases immune cell activation and differentiation, promotes angiogenesis, and activates tissue invasion\[[@B42]\].

Dapito et al\[[@B53]\] showed that translocation of components of intestinal bacterial, and Toll-like receptor 4 (TLR4), can reach the liver by the portal circulation. Both components promote liver inflammation, increasing the secretion of growth factor, such as epiregulin from hepatic stellate cells, and promoting the synthesis of ECM. This scenario enhances fibrosis and HCC development.

The microenvironment not only creates favorable conditions to develop the unregulated cell proliferation characteristic of cancer cells, but also influences their sensitivity to drugs and promotes metastasis. HGF delivered by stromal cells has been described as a key factor to confer resistance to molecular targeted drugs\[[@B54]\].

EPIGENETICS IN HCC
==================

Only 2% of the human genome encodes proteins, and the majority of the transcriptome contains non-coding RNAs (ncRNAs). ncRNAs have regulatory functions and may be classified by their sequence length, in micro RNAs (miRNAs), small nucleolar RNAs (snoRNAs), small interfering RNAS (siRNAs), long non-coding RNAs (lncRNAs), and very long intergenic ncRNAs (vlincRNAs)\[[@B55],[@B56]\]. However, there are other classifications based on association with annotated protein-coding genes, association with other DNA elements of known function, protein-coding RNA resemblance, association with repeats, with a biochemical pathway or stability, sequence and structure conservation, expression in different biological states, subcellular structures, and based on function\[[@B56]\]. Independently of the classification criteria, the ncRNAs have physiological relevance in genetic and epigenetic regulation, such as control of chromatin remodeling, gene transcription, protein transport and metabolism\[[@B57]\].

Dysregulation of miRNAs has been associated with alterations in cell signaling pathways playing important roles in the control of cell invasion, proliferation, and metastasis, among many other pathophysiologic processes. For instance, miR-26a. behaves as a tumor suppressor in hepatocellular carcinoma (HCC), but it shows oncogenic properties in lung cancer. These observations suggest that microenvironment also determines the roles of miRNAs in cancer (Table [1](#T1){ref-type="table"}). A RNA-sequencing study performed in 23 liver biopsies, between tumor and adjacent non-tumor tissue, showed 57 lncRNA with differential expression\[[@B58]\].

###### 

MicroRNA involved in hepatocellular carcinoma and their function in the hepatocyte growth factor/c-Met axis

  **miRNA**                              **Functions**                                                               **Effect of miR in HGF/c-Met axis**      **Levels in HCC**   **Ref**.
  -------------------------------------- --------------------------------------------------------------------------- ---------------------------------------- ------------------- -----------
  miR-34                                 Cell invasion, proliferation                                                Inhibits c-Met                           Downregulated       \[83\]
  miR-199                                Proliferation, cell motility,                                               Tumor-suppressor                         Downregulated       \[84\]
  cell invasion                                                                                                                                                                   
  miR-340                                Cell invasion, cell migration                                               Inhibits c-Met                           Downregulated       \[85\]
  miR-126                                Cell proliferation,                                                         Inhibits c-Met                           Downregulated       \[86\]
  cell invasion, inhibits angiogenesis                                                                                                                                            
  miR181-a                               Cell motility and invasion                                                  Inhibits c-Met                           Upregulated         \[87\]
  let-7 family                           Represses cell proliferation, invasion, metastasis and resistance therapy   Inhibits c-Met signaling downstream      Downregulated       \[88,89\]
  miR-148                                Promotes apoptosis, suppress cell invasion                                  Tumor-suppressor                         Downregulated       \[90\]
  miR-1                                  Cell migration, cell proliferation                                          Tumor-suppressor                         Downregulated       \[91\]
  miR-26a                                Cell proliferation, invasion, and migration                                 Inhibits c-Met signaling downstream      Downregulated       \[92\]
  miR-122                                Induces apoptosis                                                           Inhibition of c-Met                      Downregulated       \[93\]
  miR-145                                Cell viability, cell migration                                              Inhibits c-Met signaling downstream      Downregulated       \[94\]
  miR-449                                Promotes apoptosis, reduces proliferation                                   Decreases c-Met levels                   Downregulated       \[95\]
  miR-200                                Cell migration and invasion                                                 Decreases HGF-synthesis in fibroblasts   Upregulated         \[96\]
  miR-101                                Cell proliferation, migration and invasion                                  Inhibits c-Met signaling downstream      Downregulated       \[97\]

HCC: Hepatocellular carcinoma; HGF: Hepatocyte growth factor.

Histones acetylation, methylation, phosphorylation, sumoylation, and ubiquitylation, are post-translational modifications (PTMs) intimately related to epigenetic processes. These PTMs are responsible for the induction or repression of genes through modification in the level of DNA compaction or the recruitment of transcriptional machinery. Histones deacetylases (HDACs) are a family of proteins that remove acetyl groups from histone tail amino acids, decreasing gene expression. This family of proteins is overexpressed in HCC\[[@B59]\]. In fact, human HCC hallmarks are the loss of acetylation in H4K16\[[@B60]\], and increased methylation in H3K27 by EZH2 methylase\[[@B61]\]. Furthermore, EZH2 can inhibit the expression of miR-622, thus increasing the severity of HCC\[[@B62]\]. SET8 is a specific H4K20 methylase required for S phase progression by coupling to PCNA\[[@B63]\]. SET8 dysregulation has been described in human HCC\[[@B55]\]. Histone hypermethylation has also been related with decreased gene expression.

On the other hand, histones acetyltransferases (HAT) are a family of proteins that add acetyl groups to histone amino acids, inducing the relaxation of DNA strains, and subsequently up-regulating gene expression.

In the liver, xenobiotics such as alcohol can alter the epigenetic state by generating reactive oxygen species (ROS) and depleting S-adenosylmethionine (SAM) levels. This promotes H3K9 acetylation and alters the expression of several miRNAs\[[@B64]\]. Changes in the microbiota and viral liver infections can also modify DNA methylation, altering gene expression\[[@B65],[@B66]\].

THERAPIES
=========

HCC is difficult to diagnose by current methods with biopsy being the most validated method. However, it is difficult to obtain a representative biopsy sample because open tumor biopsies of HCC are not allowed\[[@B67]\]. This scenario makes difficult to perform an accurate diagnostic.

Chronic liver diseases caused by hepatitis virus B and/or C virus are the most prevalent causes of HCC. However, other factors have been related to increase the prevalence of HCC such alcohol-related liver diseases, obesity, and type 2 diabetes mellitus-related non-alcoholic fatty liver\[[@B45]\].

The HGF/c-Met axis has been proposed as a key target for clinical intervention. This is due to its relevance in cellular processes such as 3D morphogenesis, cell survival and metastasis. Due to their key role in HCC, HGF and c-Met have been proposed as essential therapeutic targets (Table [2](#T2){ref-type="table"}). A recent review on the therapeutic targeting of the HGF/c-Met signaling in HCC has focused on small c-Met kinase inhibitors\[[@B68]\]. This same review also comments problems as resistance to c-Met targeting drugs and side effects of c-Met targeting.

###### 

Compounds used in clinical trials to treat hepatocellular carcinoma patients

  **Agent**              **Targets**                           **Phase**   **Activity**                    **HCC stage**   **Ref**.
  ---------------------- ------------------------------------- ----------- ------------------------------- --------------- ----------
  Sorafenib              Raf, MAPK, VEGFR, PDGFRβ              III         Anti-tumor                      Advanced        \[98\]
  Anti-angiogenesis                                                                                                        
  Cabozanitinib          VEGFR2, KIT, RET, AXL                 III         Anti-tumor                      Advanced        \[99\]
  Brivanib               FGFR, VEGFR                           II          Anti-angiogenesis               Advanced        \[100\]
  Foretinib              FLT1, PDGFRβ, c-Met, VEGFR-2, Tie-2   II          Anti-tumor                      Advanced        \[101\]
  FLT4, RON, FLT3, KIT   Anti-angiogenesis                                                                                 
  Everolimus             mTOR                                  III         Anti-tumor                      Advanced        \[102\]
  Cobazitinib            c-Met, VEGFR-2, RET                   II          Anti-tumor                      Advanced        \[103\]
  Anti-angiogenesis                                                                                                        
  Ramucirumab            VEGFR-2                               III         Anti-angiogenesis               Advanced        \[104\]
  MSC2156119J            c-Met                                 Ib/II       Anti-tumor, anti-mestastasis    Advanced        \[105\]
  Gefitinib              EGFR, c-Met, HGF,                     II          Anti-tumor                      Advanced        \[106\]
  Bevacizumab            VEGFRs                                II          Anti-angiogenesis               Advanced        \[107\]
  AZD6244                MEK1/2                                Ib          Anti-tumor                      Advanced        \[108\]
  AZD4547                p-FGFR-1, p-FGFR-2                    I           Anti-tumor, anti-angiogenesis   Advanced        \[109\]
  p-c-Met,                                                                                                                 
  p-AKT,                                                                                                                   
  p-ERK                                                                                                                    
  MK2461                 c-Met, Ftl-1                          I           Anti-tumor                      Advanced        \[110\]
  Crizotinib             p-c-Met                               Ib          Anti-angiogenesis               Advanced        \[111\]
  ALK                                                                                                                      
  Bortezomib             Proteasome inhibitor                  II          Anti-tumor                      Advanced        \[102\]
  Docetaxel              EGFR                                  II          Anti-tumor                      Advanced        
  INC280                 p-c-Met                               II          Anti-tumor                      Advanced        \[111\]

HCC: Hepatocellular carcinoma.

Although some improvements have been obtained in HCC therapy, this cancer still remains largely incurable. Nowadays, there is palliative therapy using a multikinase inhibitor, such as sorafenib, which limits cell proliferation, and tumor angiogenesis\[[@B69]\]. Many clinical trials have shown that sorafenib improves overall survival of patients with advanced HCC. However, there is no effective treatment for HCC based on conventional monotherapies using tyrosine kinase inhibitors. For example, a monotherapy with Tivantinib, a small molecule tyrosine kinase inhibitor exhibiting a high selectivity against c-Met, was clinically tested. Unfortunately, in a phase III clinical trial, this compound failed to meet the primary endpoint.

HCC develops resistance to the conventional chemotherapy and radiotherapy treatments\[[@B7]\]. Moreover, the tumor microenvironment blocks drug effects\[[@B70]\]. HGF confers resistance of HCC to inhibitors of EGFR. On the other hand, HGF decreases the expression of E-cadherin\[[@B71]\] and increases the expression of Snail 1, to protect cancer cells from apoptosis\[[@B72]\].

Novel strategies against HCC
----------------------------

Another difficulty in detecting HCC is the lack of a clinically relevant circulating biomarker. Current investigations are focused on discovering circulating biomarkers\[[@B45]\]. Sitia et al\[[@B73]\] showed that the CD8^+^ T cell/platelet ratio could be a sign of HCC progression. Moreover, Sitia et al\[[@B73]\] verified that aspirin or clopidogrel, two anti-platelet drugs, decreased the number of CD8^+^ T cells in liver infected with hepatitis B virus. After treatment with anti-platelet drugs, they observed a decrease in inflammation, fibrosis severity, and progression to HCC in a transgenic mouse model\[[@B73]\]. The effect was enhanced when mice were treated with aspirin and clopidogrel. The authors concluded that anti-platelet drugs diminished the amount of CD8^+^ T cells into the liver, avoiding hepatocellular necrosis, hepatocyte regeneration, and inflammation. These events prevent or delay HCC in the mouse model used. On the other hand, this treatment does not eradicate the viral infection.

Preclinical studies in animals have shown that anti-lymphangiogenic strategies, sequestering VEGF-C and VEGF-D, or blocking VEGFR-3 with antibodies, are feasible therapies against HCC tumors\[[@B74]\]. Experimental therapy against Nrp-2 reduced tumor lymphangiogenesis, apparently delaying the departure of cells from the primary tumor\[[@B44]\]. Lymphatic cells release CXCL12, which can be blocked with antibodies and may provide therapeutics benefits\[[@B75]\]. Inhibiting the expression of Nrp-1revealed that Nrp-1 is required to activate VEGFR-2 signaling-dependent mitogenic\[[@B76]\].

Novel anticancer strategies are emerging based on ncRNA expression, because they have a myriad of cell functions, such as chromatin remodeling, protein transport, genes transcription and metabolism\[[@B57],[@B77]\]. MicroRNAs (miRs) are being studied in cancer for their key role as post-transcriptional regulators of gene expression, and for their potential to be used to classify tumors\[[@B78]\]. Recently studies are revealing that some miRNAs could be useful as prognostic biomarkers based on their presence in serum. They could be promising therapeutic targets as well.

Combinations of current drugs used for clinical treatments, such as sorafenib, tivantinib, 5-fluorouracil (5-FU), and potential miRs inhibitors, such as miR-93 inhibitor, are proposed as promising anti-HCC therapies\[[@B79]\]. Other studies demonstrated that miR26\[[@B80]\], miR-499, miR-30a, miR-122, and miR-148, among others, play a role in the development of normal physiological function in liver.

Some anti-cancer therapies against HCC are focused on HDACs as key targets. HDAC inhibitors (either miRNAs or small molecule HDAC inhibitors) have been shown to increase apoptosis and decrease cell proliferation. HCC treated with trichostatin A (TSA), a compound described as HDAC inhibitor, as well as with siRNA against HDACs (-1, -2, and -3) have increased apoptosis and decreased cell proliferation\[[@B60]\]. Sirtuins, vorinostat, romidepsin, belinostat, panobinastat, valproate and ITF2357 are HDAC inhibitors that have shown promising anti-cancer effects in clinical trials\[[@B55]\].

Histone methyltransferases, such as SET8, SUV39H1 and EZH2, are also promising targets for HCC therapy. Experiments performed in HCC cells showed that the silencing of EZH2 decreased the expression of CDKN2A, FOXO3, E2F1 and NOTCH2\[[@B81]\]. The silencing of EZH2 also repressed the expression of miR-622, increasing CXCR4 levels\[[@B61]\]. Small molecule inhibitors against EZH2, such as EPZ011989, may be potentially useful for the treatment of HCC patients\[[@B82]\].

The discovery of novel molecules related with HGF/c-Met axis signaling pathways presents a promising clinically avenue for predicting individual susceptibility and designing better specific personal therapies (Table [3](#T3){ref-type="table"}).

###### 

List of compounds analyzed in laboratories that show potential anti-tumor properties against hepatocellular carcinoma

  **Agent**                                              **Target**                                   **Activity**                                    **Ref**.
  ------------------------------------------------------ -------------------------------------------- ----------------------------------------------- ----------
  LZ8                                                    Inhibits the expression of c-Met, ERK, AKT   Induces apoptosis                               \[112\]
  Inhibits the phosphorylation of JNK, AKT, ERK, p-AKT                                                                                                
  Stabilizes p53                                                                                                                                      
  Damnacanthal                                           Inhibits the phosphorylation of c-Met        Inhibits cell proliferation and cell invasion   \[113\]
  Decreases MMP-2 activity                                                                                                                            
  GEN-203                                                Inhibits the phosphorylation of c-Met        Blocks cell proliferation                       \[114\]
  JNJ38877605                                            Inhibits phosphorylation of c-Met            Induces apoptosis                               \[70\]
  SRI31215                                               Blocks pro-HGF activation                    Inhibits cell proliferation                     \[70\]
  Madecassoside                                          Inhibits the phosphorylation of ERK1/2 and   Blocks cell proliferation                       \[115\]
  PKC                                                                                                                                                 
  PHA665752                                              Inhibits phosphorylation of c-Met and FGFR   Blocks cell proliferation                       \[116\]
  EPZ011989                                              Inhibits histone methylation                 Blocks cell proliferation                       \[82\]
  YC-1                                                   Inhibits the DNA synthesis                   Arrests cell cycle and induce apoptosis         \[117\]

CONCLUSION
==========

HCC is a complex pathology with interconnected regulatory networks involved. This cancer is difficult to diagnose and the current treatments only produce modest therapeutic benefits. Moreover, the lack of biomarkers for early diagnosis contributes to making HCC one of the cancer types with the poorest prognosis. Novel approaches to elucidate the molecular etiology of HCC have shown that, in addition to the HGF/c-Met axis signaling, there are other receptors and ligands involved. Dysregulation in protein interactions, lncRNAs, post-translational modifications in histones, and DNA methylation levels can be responsible for cell proliferation, migration, invasion, and mestastasis. Novel treatments are being developed against HDACs, methyltransferases, and miRs, among other molecular targets. Therapies combining HGF/c-Met signaling pathway inhibitors with epigenetic inhibitors, such as histone methyltransferase or HDAC inhibitors, seem to be the most promising therapies to date. Additional experimental efforts will be needed to identify useful predictive biomarkers and to suggest new personal therapies.
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